Cardiovascular toxicity of tyrosine kinase inhibitors
Authors:
- 8 April 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 12 (5) , 687-696
Abstract
(2013). Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opinion on Drug Safety: Vol. 12, No. 5, pp. 687-696. doi: 10.1517/14740338.2013.788642Keywords
This publication has 42 references indexed in Scilit:
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI: Journal of the National Cancer Institute, 2011
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a BiomarkerSeminars in Nephrology, 2010
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of TreatmentClinical Cancer Research, 2009
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problemDrug Discovery Today, 2008
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer TherapeuticsCirculation, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving TargetCancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007